REDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2025.
Rezolute, Inc.'s NASDAQ: RZLT stock price is steadily moving higher in 2025 and is expected to continue its run because of what adds up to a rapidly improving outlook. Its lead pharmaceutical candidate, Ersodetug, was granted the FDA's Breakthrough Therapy designation, which puts it on a fast track for approval.
Rezolute is advancing ersodetug in two phase 3 trials for hyperinsulinism: sunRIZE for congenital HI and upLIFT for tumor HI, respectively. RZLT secured FDA alignment for the upLIFT pivotal trial, allowing for an open-label design and only needing to recruit 16 patients. Topline data for sunRIZE is expected in December 2025, while upLIFT results are anticipated in the second half of 2026, offer...
Rezolute, Inc. (NASDAQ:RZLT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Nevan Elam - Founder, CEO, Principal Financial Officer & Acting Chairman of the Board Conference Call Participants Kelly McCarthy Presentation Kelly McCarthy All right. Good afternoon, everyone.
Open-label study in as few as 16 tumor hyperinsulinism (HI) patients Study initiated and enrolling patients in the U.S. and Europe Topline data expected in the second half of 2026 REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today...
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug
REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 29-30, 2025.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.